Entrada Therapeutics

We're on a mission to develop intracellular therapeutics to treat serious diseases. If you're passionate about contributing to groundbreaking scientific and therapeutic advances, we want you on our team!   Apply today: https://lnkd.in/eXjmC27B   #Hiring #Biotech #EntradaHere

Yesterday, Dipal Doshi, Entrada’s Chief Executive Officer, spoke at Boston CEO on the ‘Company Formation: Building A Biotech’ panel. A big thanks to Longwood Healthcare Leaders for hosting this event, as well as the other panelists who contributed to an engaging conversation.    #EntradaHere #Biotech #BostonCEO

We are delighted to watch our team grow. Please join us in welcoming our newest Entradans: · Gregory Jones, Ph.D. (Associate Director, Drug Product Development & Manufacturing) · Jasmine Feng (Senior Research Associate, Ocular Research) · David Weinstein, MD, PhD (Vice President, Clinical Development) We would also like to congratulate Owen W. Erickson (Specialist, Patient Advocacy & Corporate Affairs) who recently transitioned from a contractor role to full-time Entradan. We are thrilled to have you on our team! Interested in joining our team of dedicated Entradans? Explore our careers page and apply: https://lnkd.in/eXjmC27B #TopPlaceToWork #EntradaHere #Hiring

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

Last week, the Entrada team traveled to Prague for the 29th Annual Congress of the World Muscle Society. Natarajan Sethuraman, PhD, President of Research and Development, and Sweta Girgenrath, PhD, Vice President, Neuromuscular, presented clinical and preclinical data in support of our expanding Duchenne franchise.    If you missed the presentations, they are available here: https://lnkd.in/ed8345DB   #WMS2024 #Duchenne #DMD

As part of our Hispanic Heritage Month celebration, Entrada hosted a panel discussion to spotlight the diversity in our Hispanic and Latinx community! The conversation explored how their backgrounds influenced their life choices while also sharing ideas about inclusion and belonging at work. Each panelist ended with a favorite memory from their culture.    Please join us in giving a round of applause to our panelists: Jia Qi Cheng Zhang, PhD, Scientist I Arianna Bonilla, Senior Research Associate Paulina Baca, Senior Research Associate Weimer Macuri-Espinoza, Research Associate I   A big thank you to our amazing moderator Sara Blake, Senior Research Associate, for facilitating the discussion! We’d also like to thank Nelsa Estrella, Ph.D., Director of Neuromuscular Therapeutics, for her leadership and pulling together such a special event!     #EntradaHere #HispanicHeritageMonth #MesdelaHerenciaHispana

On this Indigenous Peoples' Day, Entrada Therapeutics pays tribute to the resilience, wisdom and rich cultural heritage of Indigenous communities worldwide. Let us celebrate by honoring the knowledge, traditions and contributions of Indigenous communities, and by working together towards a healthier and more equitable future.    #IndigenousPeoplesDay #Biotech #EntradaHere

This past week, the Entrada team attended the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada. There were poster presentations by Xiulong (Mark) Shen, PhD, Senior Scientist II, Discovery Research, and Xiang Li, PhD, Director, Discovery Research. It was a great opportunity to connect with colleagues, learn about exciting new discoveries and breakthroughs in the field, and gain valuable insights from experts.   If you missed the poster presentations, they can be viewed here: https://lnkd.in/ed8345DB   #OTS2024 #Biotech #DMD

Today, on World Mental Health Day, Entrada reaffirms our commitment to building a culture where everyone can belong, contribute and grow.    One way we do this is through our partnership with Headspace, a benefit platform that offers mental health services for our entire workforce and their families. Whether it's behavioral health coaching, therapy, psychiatry, or self-care resources, Headspace provides support and guidance, ensuring that our employees have access to the care they need.   #WorldMentalHealthDay #WMHD2024 #EntradaHere

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society.   “We are excited to present these data which support the advancement of our Duchenne franchise. Adding to our previously reported positive data from our Phase 1 ENTR-601-44-101 trial, we are presenting further safety data demonstrating that there were no adverse findings or clinically relevant changes to any biomarkers of renal toxicity measured at the highest dose tested during the study. We are also pleased to present new data from preclinical studies of ENTR-601-45, showing compelling in vivo dystrophin production and functional improvement,” said Natarajan Sethuraman, PhD, President of R&D at Entrada Therapeutics.   The posters will be presented today, October 9, during Poster Session 2 (DMD Treatments, 5:15-6:15 pm CET) and will be available on the Scientific Presentations page of the Company’s website.   For further details, visit: https://lnkd.in/eN47kVFz